[1] Gaonkar PP, Patankar SR, Tripathi N, et al. Locally aggressive benign odontogenic neoplasms-a review [J]. Inter J Oral Health Dent, 2016, 2(1):15-18. [2] Barnes L, Eveson JW, Reichart PA, et al. World Health Organization classification of tumours: pathology and genetics of head and neck tumours [M]. Lyon: IARC, 2005: 306-307. [3] Trouvin AP, Go?觕b V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss [J]. Clin Interv Aging, 2010, 5: 345-354. [4] Nonaka CF, Cavalcante RB, Nogueira RL, et al. Immunohistochemical analysis of bone resorption regulators (RANKL and OPG), angiogenic index, and myofibroblasts in syndrome and non-syndrome odontogenic keratocysts[J]. Arch Oral Biol, 2012, 57(3): 230-237. [5] August M, Faquin WC, Troulis MJ, et al. Differentiation of odontogenic keratocyst epithelium after cyst decompression [J]. J Oral Maxillofac Surg, 2003, 61(6): 678-684. [6] 胡永杰, 李思毅, 张陈平. 开窗减压术治疗下颌骨大型囊性病变的临床研究 [J]. 口腔颌面外科杂志, 2005, 15(4): 352-356. [7] Kaplan I, Hirshberg A. The correlation between epithelial cell proliferation and inflammation in odontogenic keratocyst [J]. Oral Oncol, 2004, 40(10): 985-991. [8] Trouvin AP, Go?觕b V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss [J]. Clin Interv Aging, 2010, 5: 345-354. [9] Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond [J]. Front Immunol, 2014, 5: 511. [10] Tarcília AS, Elismauro FM, Sandra F, et al. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2008, 105(3):333-341. [11] Felipe RM, Maiara M, Cassiano FWN, et al. Immunohistochemical detection of receptor activator nuclear κB ligand and osteoprotegerin in odontogenic cysts and tumors[J]. J Oral Maxillofac Surg, 2013, 71(11):1886-1892. |